Overview: Melanotan II is Schedule 4 and not ARTG-approved for tanning in Australia. Read the human evidence, mole and melanoma limits, safety risks and TGA advice.
On this page
Melanotan II (MT2) can increase skin pigmentation, but that proof-of-mechanism is not proof of a safe tanning medicine. Early human research was small, modern consumer products have not passed Australian approval, and the most important current facts are regulatory and safety related.
Australia status checked 30 September 2026: Melanotan II is listed in Schedule 4 of the current Poisons Standard. The TGA states that there are no Melanotan II products on the Australian Register of Therapeutic Goods (ARTG) and none approved for supply in Australia. It is not approved for sale or use as a tanning agent.
Evidence boundary: this page explains published research and official Australian information. It does not provide dosing, administration, sourcing or personal treatment advice.
Melanotan II at a glance
| Question | Evidence-based answer |
|---|---|
| What is MT2? | A synthetic cyclic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates several melanocortin receptors. |
| Can it darken skin? | Small early human studies showed increased pigmentation. That does not establish an acceptable benefit–risk profile for unsupervised tanning use. |
| Is it approved for tanning in Australia? | No. The TGA says it is not approved for sale or use as a tanning agent and that no Melanotan II products are currently on the ARTG. |
| Is it prescription-only? | Yes. Melanotan II appears in Schedule 4 of the Therapeutic Goods (Poisons Standard—October 2026) Instrument. |
| Does it cause melanoma? | A causal relationship has not been established. Case reports describe new or changing naevi and melanomas after use, often with UV exposure and other confounding. That is a safety signal, not proof of causation. |
| Does darker skin from MT2 prevent UV damage? | No. The TGA states that no tan—artificial or natural—protects against UV damage in the way a suitable sunscreen does. |
What Melanotan II is—and what it is not
Melanotan II is a synthetic, cyclic peptide developed from α-MSH biology. It is a non-selective melanocortin receptor agonist. Activity at melanocortin receptors helps explain pigmentation, appetite effects, nausea, yawning and sexual effects reported in early studies and case reports.
The name is easily confused with two related but distinct medicines. Afamelanotide is a different α-MSH analogue with a product-specific regulatory record and a narrow medical indication in some jurisdictions. Bremelanotide is a related melanocortin agonist developed for a defined sexual-health indication in the United States. Neither product’s evidence or approval can be transferred to Melanotan II sold online.
| Compound | Evidence and regulatory context | Do not infer |
|---|---|---|
| Melanotan II / MT2 | Experimental tanning and melanocortin research; Schedule 4 in Australia; no ARTG product | That an online vial or nasal spray is an approved medicine |
| Afamelanotide | Distinct analogue and regulated product for a specific medical indication in certain jurisdictions | That approval covers cosmetic tanning or MT2 |
| Bremelanotide / PT-141 | Distinct product and clinical programme for a narrowly defined indication | That it validates MT2 for tanning or general sexual enhancement |
For the separate bremelanotide evidence record, see our PT-141 and bremelanotide research profile.
What the human evidence actually shows
Early proof-of-mechanism studies
A 1996 pilot Phase I study reported that Melanotan II produced tanning activity after a short series of exposures. Mild nausea occurred at several studied levels, and a yawning-and-stretching response coincided with spontaneous erections. This establishes biological activity in humans. It does not establish that repeated cosmetic use is safe, that an internet product matches the study material, or that benefits outweigh harms.
Why the evidence remains limited
The clinical record is not a modern registration programme for cosmetic tanning. The early studies were small and designed around pharmacology and pigmentation, not long-term cancer outcomes, cardiovascular safety, contaminated products, repeated unsupervised exposure or diverse real-world users.
| Evidence type | What it can support | What it cannot settle |
|---|---|---|
| Small early human studies | Receptor activity, pigmentation and short-term adverse effects under study conditions | Long-term safety, consumer-product quality or population-wide benefit–risk |
| User interviews and surveys | Motivations, behaviours, sunbed use and reported experiences | Causation or incidence of rare harms |
| Dermatology case reports | Signals such as new or changing naevi that warrant investigation | How often an event occurs or whether MT2 alone caused it |
| Regulator surveillance | Current legal status, product-quality concerns and reported risks | Proof that every product contains the labelled substance |
Moles, melanoma and the limits of causal claims
The careful conclusion is neither “MT2 definitely causes melanoma” nor “there is no concern.” Published case reports describe rapid darkening, enlargement or eruption of melanocytic naevi after unregulated melanotan use. Reviews also describe melanoma diagnoses occurring during or after use. However, many reports involve small numbers, prior melanoma risk, dysplastic naevi, sun-seeking behaviour or sunbed exposure. Those factors make causation difficult to isolate.
The evidence does establish a practical safety problem: a substance intended to stimulate pigment cells can alter the appearance of lesions that clinicians monitor for skin cancer, while some users also increase ultraviolet exposure. New, changing, bleeding or otherwise concerning lesions need qualified clinical assessment; online before-and-after photographs cannot rule out malignancy.
Important distinction: a case report can identify a credible warning signal, but it cannot calculate risk or prove causation. Conversely, the absence of a controlled long-term cancer trial is not evidence of safety.
Reported adverse effects and product-quality risks
The TGA lists common reported effects including headache, nausea, vomiting, reduced appetite and facial redness. Early research and later case reports also describe yawning, spontaneous erections and priapism. A published toxicology case confirmed Melanotan II by mass spectrometry after an internet-purchased product was associated with severe systemic toxicity, rhabdomyolysis and renal dysfunction. A single case cannot estimate frequency, but it demonstrates that clinically serious toxicity is possible.
- Melanocortin effects: nausea, flushing, appetite change, yawning and sexual effects.
- Pigmentary effects: darkening of freckles or existing naevi and the appearance of new pigmented lesions.
- Serious case reports: priapism, systemic toxicity, muscle injury and renal complications.
- Product risks: uncertain identity, strength, sterility, endotoxin, impurities, storage history and counterfeit labelling.
- Behavioural risk: using sunbeds or extra UV exposure because a tan is mistaken for protection.
Anyone with severe symptoms or a prolonged painful erection should seek urgent medical care. In Australia, the Poisons Information Centre can be reached on 13 11 26; call 000 for a life-threatening emergency.
What did TGA testing find in August 2026?
In its 17 August safety advisory, the TGA described five seized nasal-spray bottles labelled as containing 30 mg of Melanotan II. Laboratory estimates ranged from 22 mg to 54 mg per bottle, calculated using the labelled volume.
Those measurements describe the five tested bottles. They do not establish the contents of every product using the same molecule name,. The finding illustrates a product-quality problem that cannot be resolved by appearance or a label claim alone. Advisory checked: 22 October 2026.
Melanotan II in Australia: the current regulatory picture
The current position is unusually clear:
- Schedule 4: the October 2026 Poisons Standard names Melanotan II in Schedule 4. Regulatory source checked: 22 October 2026.
- No ARTG product: the TGA stated on 21 May 2026 that no products containing Melanotan II were on the ARTG or approved for supply in Australia.
- No tanning approval: the TGA states that Melanotan is not approved for sale or use as a tanning agent.
- Active enforcement: the TGA announced 27 paid infringement notices totalling A$101,412 over alleged unlawful supply to Australian consumers.
Scheduling, ARTG inclusion and a permitted therapeutic indication answer different questions. Schedule 4 does not mean that a product is TGA-approved, and a “research use only” label does not override therapeutic-goods law. For the framework, read our Australia and TGA regulation guide.
Why a purity certificate does not establish safety
An HPLC peak-area result can help describe chromatographic composition under the stated method. It does not by itself prove identity, amount per vial, sterility, endotoxin control, absence of every impurity, stability or lawful supply. Even a genuine identity result would not create clinical approval.
Use our lab test versus TGA approval guide to separate analytical evidence from regulatory evidence, and our HPLC chromatogram guide for method-specific interpretation.
Frequently asked questions
Is Melanotan II legal in Australia?
Melanotan II is Schedule 4. The TGA states that there are no Melanotan II products on the ARTG and none approved for supply in Australia. Individual circumstances can involve Commonwealth and state or territory controls, so “legal” is not answered by a seller’s label or overseas availability.
Is MT2 approved for tanning?
No. The TGA says Melanotan is not approved for sale or use as a tanning agent in Australia.
Does MT2 prevent sunburn or skin cancer?
No. Artificially increased pigmentation is not a substitute for sunscreen, protective clothing, shade or other evidence-based UV protection. The TGA explicitly warns that no tan protects against UV damage in the way suitable sunscreen does.
Does Melanotan II cause melanoma?
Case reports and reviews describe melanoma and changing naevi in temporal association with use, but they do not prove that MT2 alone caused those cancers. UV exposure and baseline risk are important confounders. The uncertainty itself matters because MT2 is unapproved and long-term controlled safety evidence is absent.
Is Melanotan II the same as bremelanotide?
No. They are related melanocortin agonists with different molecules, products, evidence bases and regulatory histories. Evidence for bremelanotide cannot be used as approval evidence for MT2.
Can a “99% HPLC purity” claim prove an MT2 vial is safe?
No. HPLC peak area is method-dependent and does not by itself establish identity, dose accuracy, sterility, endotoxin, stability, clinical safety or approval.
Primary and official sources
- TGA: 27 infringement notices for alleged Melanotan II supply, 21 May 2026.
- TGA: Don’t risk tanning products containing melanotan, 24 January 2025.
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026.
- Dorr et al. Evaluation of Melanotan II in a pilot Phase I study, 1996.
- Habbema et al. Review of risks from unregulated α-MSH analogues, 2017.
- Cardones et al. Eruptive naevi after synthetic α-MSH use, 2009.
- Nelson et al. Systemic toxicity and rhabdomyolysis case report, 2012.
- Gilhooley et al. Qualitative study of Melanotan II user experience, 2021.
Reviewed 30 September 2026. Educational information only; no dosing, administration, sourcing or personal medical advice.
How to cite this research profile
Melanotan II Australia: TGA Status, Evidence and Safety Risks. Elite Peps Australia. Published 30 June 2026; updated 23 October 2026. https://elitepepsaustralia.com/product/mt-2/
Verification: Follow the linked primary studies, trial records and regulator documents in the references above. Regulatory status is date-sensitive.